BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 34591491)

  • 1.
    Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
    Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
    Zhang C; Yuan W; Wu Y; Wan X; Gong Y
    Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.
    Yang YY; Zhang W; Liu H; Jiang JJ; Wang WJ; Jia ZY
    Drug Des Devel Ther; 2021; 15():4961-4972. PubMed ID: 34916779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.
    Zhao Z; Li Y; Shukla R; Liu H; Jain A; Barve A; Cheng K
    Theranostics; 2019; 9(15):4508-4524. PubMed ID: 31285776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localized RNA interference therapy to eliminate residual lung cancer after incomplete microwave ablation.
    Cao F; Wan C; Xie L; Qi H; Shen L; Chen S; Song Z; Fan W
    Thorac Cancer; 2019 Jun; 10(6):1369-1377. PubMed ID: 31017731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-assembled redox-responsive BRD4 siRNA nanoparticles: fomulation and its in vitro delivery in gastric cancer cells.
    Zhang M; An Z; Jiang Y; Wei M; Li X; Wang Y; Wang H; Gong Y
    J Chemother; 2024 Jan; ():1-15. PubMed ID: 38291982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of polyethylene glycol-grafted polyethylenimine and superparamagnetic iron oxide nanoparticles (PEG-g-PEI-SPION) as an MRI-visible vector for siRNA delivery in gastric cancer in vitro and in vivo.
    Chen Y; Lian G; Liao C; Wang W; Zeng L; Qian C; Huang K; Shuai X
    J Gastroenterol; 2013 Jul; 48(7):809-21. PubMed ID: 23179610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
    Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
    Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
    Lu ZX; Liu LT; Qi XR
    Int J Nanomedicine; 2011; 6():1661-73. PubMed ID: 21904456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutathione-sensitive RGD-poly(ethylene glycol)-SS-polyethylenimine for intracranial glioblastoma targeted gene delivery.
    Lei Y; Wang J; Xie C; Wagner E; Lu W; Li Y; Wei X; Dong J; Liu M
    J Gene Med; 2013; 15(8-9):291-305. PubMed ID: 24038955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy.
    Jing H; Cheng W; Li S; Wu B; Leng X; Xu S; Tian J
    Colloids Surf B Biointerfaces; 2016 Oct; 146():387-95. PubMed ID: 27388967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
    Vaidya AM; Sun Z; Ayat N; Schilb A; Liu X; Jiang H; Sun D; Scheidt J; Qian V; He S; Gilmore H; Schiemann WP; Lu ZR
    Bioconjug Chem; 2019 Mar; 30(3):907-919. PubMed ID: 30739442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro.
    Wu Y; Wang W; Chen Y; Huang K; Shuai X; Chen Q; Li X; Lian G
    Int J Nanomedicine; 2010 Mar; 5():129-36. PubMed ID: 20309399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles.
    Liu Y; Zhu YH; Mao CQ; Dou S; Shen S; Tan ZB; Wang J
    J Control Release; 2014 Oct; 192():114-21. PubMed ID: 25016158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.
    Yu MZ; Pang WH; Yang T; Wang JC; Wei L; Qiu C; Wu YF; Liu WZ; Wei W; Guo XY; Zhang Q
    Eur J Pharm Sci; 2016 Sep; 92():39-48. PubMed ID: 27355138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
    Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
    Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasound-guided delivery of thymidine kinase-nitroreductase dual therapeutic genes by PEGylated-PLGA/PIE nanoparticles for enhanced triple negative breast cancer therapy.
    Devulapally R; Lee T; Barghava-Shah A; Sekar TV; Foygel K; Bachawal SV; Willmann JK; Paulmurugan R
    Nanomedicine (Lond); 2018 May; 13(9):1051-1066. PubMed ID: 29790803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of cationic polymer-siRNA nanoparticles for gene therapies in neural regeneration.
    Liang Y; Liu Z; Shuai X; Wang W; Liu J; Bi W; Wang C; Jing X; Liu Y; Tao E
    Biochem Biophys Res Commun; 2012 May; 421(4):690-5. PubMed ID: 22542938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
    Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.